Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 23;41(18):3339–3351. doi: 10.1200/JCO.22.01649

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 4. — Kaplan-Meier estimates of secondary end points. (A and B) Kaplan-Meier estimates of TCC and TSP in the HRR+ cohort, respectively. (C and D) Kaplan-Meier estimates of TCC and TSP in the BRCA1/2 subgroup, respectively. (E) Kaplan-Meier estimate of OS in the HRR+ cohort. AAP, abiraterone acetate plus prednisone; HR, hazard ratio; HRR, homologous recombination repair; NE, not evaluable; NIRA, niraparib; OS, overall survival; PBO, placebo; TCC, time to initiation of cytotoxic chemotherapy; TSP, time to symptomatic progression.